J 2011

Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach-Part 1.

DWYER, Michael, Kamil PARUCH, Marc LABROLI, Carmen ALVAREZ, Kerry KEERTIKAR et. al.

Basic information

Original name

Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach-Part 1.

Name in Czech

Discovery of pyrazolo[1,5-a]pyrimidine-based CHK1 inhibitors: A template-based approach-Part 1.

Authors

DWYER, Michael (840 United States of America), Kamil PARUCH (203 Czech Republic, guarantor, belonging to the institution), Marc LABROLI (840 United States of America), Carmen ALVAREZ (840 United States of America), Kerry KEERTIKAR (840 United States of America), Cory POKER (840 United States of America), Randall ROSSMAN (840 United States of America), Thierry FISCHMANN (840 United States of America), Jose DUCA (840 United States of America), Vincent MADISON (840 United States of America), David PARRY (840 United States of America), Nicole DAVIS (840 United States of America), Wolfgang SEGHEZZI (840 United States of America), Derek WISWELL (840 United States of America) and Timothy GUZI (840 United States of America)

Edition

Bioorganic & Medicinal Chemistry Letters, Elsevier, 2011, 0960-894X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

10401 Organic chemistry

Country of publisher

United States of America

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.554

RIV identification code

RIV/00216224:14310/11:00051795

Organization unit

Faculty of Science

UT WoS

000285544400096

Keywords in English

Kinase CHK1 Pyrazolo[1 5-a]pyrimidine Template

Tags

Změněno: 5/3/2012 11:19, Ing. Zdeňka Rašková

Abstract

V originále

The synthesis and hit-to-lead SAR development of a pyrazolo[1,5-a]pyrimidine hit 4 is described leading to a series of potent, selective CHK1 inhibitors such as compound 17r. In the Letter, the further utility of the pyrazolo[1,5-a]pyrimidine template for the development of potent, selective kinase inhibitors is detailed.